Dr. Clay Siegall is a scientist and entrepreneur. He’s co-founder, president and CEO of the Bothell, Washington based cancer research company Seattle Genetics. Siegall co-founded the company in 1998 and built it on a foundation of rigorous research, scientific innovation and a passion for helping patients. In the years since its founding, the company has become an international leader in creating effective cancer treatments. Dr. Siegall has played a major role in that. He has recruited an excellent staff and provided them with the resources they need to succeed.
In addition to creating an atmosphere that encourages creativity based on research, Dr. Siegall has been a tireless fundraiser for the facility. Since founding Seattle Genetics he has led capital-raising activities with private and public sources which has netted the company in excess of $675 million. Dr. Clay Siegall has also created licensing agreements for Seattle Genetics’ ADC technologies with Pfizer, Abbvie, Genentech, GlaxoSmithliene and others that have brought in over $300 million. The antibody-drug conjugates the company developed is used in more than 60 countries.
A graduate of the University of Maryland and George Washington University, Clay Siegall bas a B.S. in Zoology and a Ph.D. in Genetics. Since graduating he has worked on cancer research with companies including Ultragenyx Pharmaceutical, Mirna Therapeutics, Inc., Alder Biopharmaceuticals Inc., the National Institutes of Health, the National Cancer Institute and Bristol-Myers Squibb Pharmaceutical Research Institute on the development of effective cancer treatments.
At Seattle Genetics he’s helped to create an excellent development pipeline of diverse antibody-based cancer therapies. It includes almost two dozen ADCs in clinical trial. In 2011, the company’s ADCETRIS became the first ADC to receive FDA approval.
Throughout his career, Dr. Siegall has won numerous awards for his groundbreaking work. They include being selected Alumnus of the Year for Computer, Math and Natural Sciences by the University of Maryland and Entrepreneur of the Year by Ernst & Young. His vision and innovation has led him to hold 15 patents. Dr. Siegall’s commitment to sharing valuable information on cancer research and treatment has resulted in him writing pieces for over 70 publications.